Literature DB >> 17040111

Antistaphylococcal vaccines and immunoglobulins: current status and future prospects.

Stan Deresinski1.   

Abstract

Staphylococci are among the most frequently encountered pathogens in both the inpatient and the outpatient setting. Management of infections caused by these organisms is complicated by the increasingly common resistance of staphylococcal pathogens to commonly used antibacterials. As a consequence, novel approaches to prevention and treatment are urgently required. Such approaches include the development of vaccines and immunoglobulin preparations targeted at virulence factors expressed in vivo by staphylococci. This article reviews the biopharmaceutical progress made to date in this field and suggests approaches to further progress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040111     DOI: 10.2165/00003495-200666140-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  58 in total

Review 1.  The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.

Authors:  P C Appelbaum
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

Review 2.  Immune evasion by staphylococci.

Authors:  Timothy J Foster
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

3.  Coagulase-negative staphylococcal sepsis in neonates. Association between antibiotic resistance, biofilm formation and the host inflammatory response.

Authors:  Claus Klingenberg; Elizabeth Aarag; Arild Rønnestad; Johanna Ericson Sollid; Tore Gunnar Abrahamsen; Gry Kjeldsen; Trond Flaegstad
Journal:  Pediatr Infect Dis J       Date:  2005-09       Impact factor: 2.129

4.  Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis.

Authors:  Christopher Weidenmaier; Andreas Peschel; Yan-Qiong Xiong; Sascha A Kristian; Klaus Dietz; Michael R Yeaman; Arnold S Bayer
Journal:  J Infect Dis       Date:  2005-04-11       Impact factor: 5.226

5.  Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections.

Authors:  Kevin B Laupland; Deirdre L Church; Melissa Mucenski; Lloyd R Sutherland; H Dele Davies
Journal:  J Infect Dis       Date:  2003-04-15       Impact factor: 5.226

6.  Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.

Authors:  Jing-Chun Cui; Dong-Liang Hu; Yan-Chun Lin; Ai-Dong Qian; Akio Nakane
Journal:  FEMS Immunol Med Microbiol       Date:  2005-02-10

7.  Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.

Authors:  John B Robbins; Rachel Schneerson; Gary Horwith; Robert Naso; Ali Fattom
Journal:  Am Heart J       Date:  2004-04       Impact factor: 4.749

8.  Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro.

Authors:  Valérie Gauduchon; Gregoire Cozon; François Vandenesch; Anne-Laure Genestier; Nathalie Eyssade; Simone Peyrol; Jerome Etienne; Gerard Lina
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

9.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.

Authors:  A Fattom; R Schneerson; D C Watson; W W Karakawa; D Fitzgerald; I Pastan; X Li; J Shiloach; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.609

10.  Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.

Authors:  P G Welch; A Fattom; J Moore; R Schneerson; J Shiloach; D A Bryla; X Li; J B Robbins
Journal:  J Am Soc Nephrol       Date:  1996-02       Impact factor: 14.978

View more
  6 in total

1.  The potential economic value of a Staphylococcus aureus vaccine for neonates.

Authors:  Bruce Y Lee; Paul J Ufberg; Rachel R Bailey; Ann E Wiringa; Kenneth J Smith; Andrew J Nowalk; Conor Higgins; Angela R Wateska; Robert R Muder
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

2.  Active and Passive Immunization Against Staphylococcus aureus Periprosthetic Osteomyelitis in Rats.

Authors:  Niels H Søe; Nina Vendel Jensen; Asger Lundorff Jensen; Janne Koch; Steen Seier Poulsen; Gerald B Pier; Helle Krogh Johansen
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

3.  Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.

Authors:  Michael L Landrum; Tahaniyat Lalani; Minoo Niknian; Jason D Maguire; Duane R Hospenthal; Ali Fattom; Kimberly Taylor; Jamie Fraser; Kenneth Wilkins; Michael W Ellis; Paul D Kessler; Rafaat E F Fahim; David R Tribble
Journal:  Hum Vaccin Immunother       Date:  2016-12-23       Impact factor: 3.452

4.  Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.

Authors:  Bruce Y Lee; Ann E Wiringa; Rachel R Bailey; G Jonathan Lewis; Jared Feura; Robert R Muder
Journal:  Vaccine       Date:  2010-01-09       Impact factor: 3.641

5.  Solonamide B inhibits quorum sensing and reduces Staphylococcus aureus mediated killing of human neutrophils.

Authors:  Anita Nielsen; Maria Månsson; Martin S Bojer; Lone Gram; Thomas O Larsen; Richard P Novick; Dorte Frees; Hanne Frøkiær; Hanne Ingmer
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 6.  The Continuing Threat of Methicillin-Resistant Staphylococcus aureus.

Authors:  Márió Gajdács
Journal:  Antibiotics (Basel)       Date:  2019-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.